Real-world study reports effects of Spiolto Respimat

Large European real-world study reports effects of Spiolto ® Respimat® for people living with COPD in daily clinical practice1OTIVACTO study reported improvements in both physical functioning and general condition in people living with COPD receiving Spiolto ®(tiotropium/olodaterol) Respimat® therapy14 out of 5 patients reported high satisfaction with their Respimat ® inhaler and tiotropium/olodaterol treatment overall1Data presented at European Respiratory Society International Congress 20181
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news